Literature DB >> 10645850

Global epidemic of human T-cell lymphotropic virus type-I (HTLV-I).

R F Edlich1, J A Arnette, F M Williams.   

Abstract

Infection with human T-cell lymphotrophic virus-I (HTLV-I) is now a global epidemic, affecting 10 million to 20 million people. This virus has been linked to life-threatening, incurable diseases: adult T-cell leukemia/lymphoma (ATLL) and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The cumulative lifetime risk of developing these incurable diseases is approximately 5% in asymptomatic patients. For the emergency physician practicing among patients from high-risk groups, HTLV-I and its associated diseases are presenting an increasing challenge. This report describes its transmission, seroprevalence, treatment, and methods of controlling spread of this retrovirus. Coinfection with HTLV-I and HIV has been shown to accelerate the progression of acquired immune deficiency syndrome (AIDS).

Entities:  

Mesh:

Year:  2000        PMID: 10645850     DOI: 10.1016/s0736-4679(99)00173-0

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  46 in total

Review 1.  Tetraspanins in viral infections: a fundamental role in viral biology?

Authors:  F Martin; D M Roth; D A Jans; C W Pouton; L J Partridge; P N Monk; G W Moseley
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 2.  Effect of transforming viruses on molecular mechanisms associated with cancer.

Authors:  Tajhal Dayaram; Susan J Marriott
Journal:  J Cell Physiol       Date:  2008-08       Impact factor: 6.384

3.  Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)/tropical spastic paraparesis (HAM/TSP) disease from HTLV-1 carrier state.

Authors:  J B Guerreiro; S B Santos; D J Morgan; A F Porto; A L Muniz; J L Ho; A L Teixeira; M M Teixeira; E M Carvalho
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

4.  High-yield production in E. coli and characterization of full-length functional p13II protein from human T-cell leukemia virus type 1.

Authors:  Elka R Georgieva; Peter P Borbat; Christina Fanouraki; Jack H Freed
Journal:  Protein Expr Purif       Date:  2020-04-30       Impact factor: 1.650

5.  Peripheral blood mononuclear cells from individuals infected with human T-cell lymphotropic virus type 1 have a reduced capacity to respond to recall antigens.

Authors:  Rita Elizabeth Mascarenhas; Cláudia Brodskyn; Geisa Barbosa; Jorge Clarêncio; Antônio Souza Andrade-Filho; Frederico Figueiroa; Bernardo Galvão-Castro; Fernanda Grassi
Journal:  Clin Vaccine Immunol       Date:  2006-05

Review 6.  Leukemogenesis of adult T-cell leukemia.

Authors:  Jun-ichirou Yasunaga; Masao Matsuoka
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

Review 7.  Incidence of adult T-cell leukemia/lymphoma in nonendemic areas.

Authors:  Noriaki Yoshida; Dai Chihara
Journal:  Curr Treat Options Oncol       Date:  2015-02

Review 8.  Critical role of human T-lymphotropic virus type 1 accessory proteins in viral replication and pathogenesis.

Authors:  Björn Albrecht; Michael D Lairmore
Journal:  Microbiol Mol Biol Rev       Date:  2002-09       Impact factor: 11.056

9.  Early neurologic abnormalities associated with human T-cell lymphotropic virus type 1 infection in a cohort of Peruvian children.

Authors:  Emily A Kendall; Elsa González; Iván Espinoza; Martín Tipismana; Kristien Verdonck; Daniel Clark; Sten H Vermund; Eduardo Gotuzzo
Journal:  J Pediatr       Date:  2009-07-22       Impact factor: 4.406

10.  HTLV-1 modifies the clinical and immunological response to schistosomiasis.

Authors:  A F Porto; S B Santos; L Alcantara; J B Guerreiro; J Passos; T Gonzalez; F Neva; D Gonzalez; J L Ho; E M Carvalho
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.